<DOC>
	<DOCNO>NCT01056341</DOCNO>
	<brief_summary>There unsatisfied medical need first-line treatment proliferate IHs good benefit/risk profile . Based recent finding encourage result obtain propranolol series infant severe Infantile Hemangioma ( IH ) , propranolol expect significant benefit management condition . The present study design confirm efficacy propranolol severe IH demonstrate superiority placebo document safety profile propranolol indication .</brief_summary>
	<brief_title>Study Demonstrate Efficacy Safety Propranolol Oral Solution Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy</brief_title>
	<detailed_description>Primary objective The primary objective study identify appropriate dose duration propranolol treatment demonstrate superiority placebo base complete/nearly complete resolution target IH W24 .</detailed_description>
	<mesh_term>Hemangioma</mesh_term>
	<mesh_term>Hemangioma , Capillary</mesh_term>
	<mesh_term>Port-Wine Stain</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Proliferating IH ( target hemangioma ) require systemic therapy anywhere body except diaper area large diameter least 1.5 cm The patient present one follow medical condition : Congenital hemangioma ; KasabachMerritt syndrome ; bronchial asthma ; bronchospasm ; hypoglycaemia ( &lt; 40 mg/dl risk ) ; untreated phaeochromocytoma ; hypotension ( &lt; 50/30 mmHg ) ; second third degree heart block ; cardiogenic shock ; metabolic acidosis ; bradycardia ( &lt; 80 bpm ) ; severe peripheral arterial circulatory disturbance ; Raynaud 's phenomenon ; sick sinus syndrome ; uncontrolled heart failure Prinzmetal 's angina ; document PHACES syndrome central nervous system involvement The patient previously treat IH , include surgical and/or medical procedure ( e.g . laser therapy ) The patient know hypersensitivity propranolol and/or betablockers One follow type IH present : Lifethreatening IH Functionthreatening IH ( e.g . cause impairment vision , respiratory compromise cause airway lesion , etc . ) Ulcerated IH ( whatever localisation ) pain lack response simple wound care measure The patient bear prematurely yet reach his/her term equivalent age ( e.g . infant born 2 month prematurely include age 2 month ) LVEF ( leave ventricular systolic function ) â‰¤40 % and/or cardiomyopathy and/or hereditary arrhythmia disorder</criteria>
	<gender>All</gender>
	<minimum_age>35 Days</minimum_age>
	<maximum_age>150 Days</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Infantile Hemangioma</keyword>
	<keyword>Propranolol</keyword>
</DOC>